The US Food and Drug Administration (FDA) has granted final approval for Alembic Pharmaceuticals’s abbreviated new drug application for travoprost ophthalmic solution USP, 0.004%, formulated as an ionic buffered solution. The FDA determined the product to be therapeutically equivalent to the reference drug Travatan Z ophthalmic solution, 0.004% (Sandoz).

Travoprost is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The newly approved generic provides an additional option within a class of medications commonly used as first-line therapy in glaucoma management. According to IQVIA, the travoprost ophthalmic solution market had estimated US sales of approximately $61 million for the 12 months ending September 2025.